Sheraton Tamarron Resort Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2001
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Neuronal and Vascular Stress: A New Window on Alzheimer's Disease (A3)
Organizer(s) David M. Stern, Samuel C. Silverstein, Michael L. Shelanski, Richard Mayeux, Lennart Mucke, Alex Roher, Berislav Zlokovic and Perry B. Molinoff
January 15—21, 2001
Sheraton Tamarron Resort • Durango, CO USA
Abstract Deadline: Sep 15, 2000
Late Abstract Deadline:
Scholarship Deadline:
Early Registration Deadline: Nov 30, 2000
Sponsored in part by the Director's Sponsor Fund
Summary of Meeting:
Recent findings have focused attention on amyloid beta-peptide (Abeta) as a key element in the pathogenicity of cell stress and, ultimately, cytotoxicity to neurons and the vasculature in Alzheimer’s disease and cerebrovascular amyloid angiopathy. Although dense, extracellular plaque-like deposits of Abeta are abundant late in the course of Alzheimer’s disease, it has become evident that much earlier events in the generation and toxicity of Abeta, especially within the endoplasmic reticulum, will be critical to fully understand in order to design therapies that block the disease at a stage when cellular dysfunction is still reversible. Biology of the presenilins, cell surface and intracellular targets of Abeta converge on microglial-neuronal interactions and the vasculature to create a milieu of sustained and destructive inflammation, as well as an exaggerated and adverse response to ischemic stress. Insights from new animal models and clinical studies will be described, and related to an emerging cell biology of Alzheimer’s disease and cerebrovascular amyloid angiopathy; namely, that of cellular dysfunction is driven by Abeta-induced engagement of specific molecular targets, rather than the previously held notion of passive cellular disruption by massive fibrils nonspecifically and inexorably destabilizing cell membranes. This altered view of the pathogenesis of Alzheimer’s disease suggests multiple sites for future therapeutic interventions.
View Scholarships/Awards
Recent findings have focused attention on amyloid beta-peptide (Abeta) as a key element in the pathogenicity of cell stress and, ultimately, cytotoxicity to neurons and the vasculature in Alzheimer’s disease and cerebrovascular amyloid angiopathy. Although dense, extracellular plaque-like deposits of Abeta are abundant late in the course of Alzheimer’s disease, it has become evident that much earlier events in the generation and toxicity of Abeta, especially within the endoplasmic reticulum, will be critical to fully understand in order to design therapies that block the disease at a stage when cellular dysfunction is still reversible. Biology of the presenilins, cell surface and intracellular targets of Abeta converge on microglial-neuronal interactions and the vasculature to create a milieu of sustained and destructive inflammation, as well as an exaggerated and adverse response to ischemic stress. Insights from new animal models and clinical studies will be described, and related to an emerging cell biology of Alzheimer’s disease and cerebrovascular amyloid angiopathy; namely, that of cellular dysfunction is driven by Abeta-induced engagement of specific molecular targets, rather than the previously held notion of passive cellular disruption by massive fibrils nonspecifically and inexorably destabilizing cell membranes. This altered view of the pathogenesis of Alzheimer’s disease suggests multiple sites for future therapeutic interventions.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
MONDAY, JANUARY 15
TUESDAY, JANUARY 16
WEDNESDAY, JANUARY 17
THURSDAY, JANUARY 18
FRIDAY, JANUARY 19
SATURDAY, JANUARY 20
SUNDAY, JANUARY 21
Conference Program Print | View meeting in 12 hr (am/pm) time
MONDAY, JANUARY 15
14:00—19:00
Registration
Alcove
18:15—19:15
Welcome
Windom Peak
19:15—19:30
Orientation
Silverton
19:30—20:30
Keynote Address
Silverton
Konrad Beyreuther,
University of Heidelberg, Germany
Alzheimer's Disease - Does Neuronal Transport Hold the Key?
Alzheimer's Disease - Does Neuronal Transport Hold the Key?
07:00—08:00
Breakfast
Antlers
08:00—11:00
The Presenilins
Silverton
*
Peter St. George-Hyslop,
Cambridge Institute for Medical Research, UK
Presenilin and Protein Trafficking
Presenilin and Protein Trafficking
Raphael Kopan,
University of Cincinnati College of Medicine, USA
Notch Signaling: A New Paradigm for Signal Transduction
Notch Signaling: A New Paradigm for Signal Transduction
Christian Haass,
Ludwig-Maximilians University Munich, Germany
The Cell Biology of beta- and gamma-Secretase
The Cell Biology of beta- and gamma-Secretase
Hui Zheng,
Baylor College of Medicine, USA
Presenilins in CNS Function and Skin Tumorigenesis
Presenilins in CNS Function and Skin Tumorigenesis
09:20—09:40
Coffee Break
Windom Peak
11:00—13:00
Poster Setup
Innisbrook/Animas
15:00—16:00
Workshop 1: Molecular Markers of AD
Silverton
*
Joseph D. Buxbaum,
Mount Sinai School of Medicine, USA
Alpha Beta in Early Dementia
Alpha Beta in Early Dementia
Elaine R. Peskind,
University of Washington, USA
Increased Cerbrospinal Fluid Cortisol in Alzheimer's Disease is a Function of Apolipoprotien E. Genotype
Increased Cerbrospinal Fluid Cortisol in Alzheimer's Disease is a Function of Apolipoprotien E. Genotype
Elizabeth H. Corder,
Duke University, USA
Brain Weight at Ages 80+ is Predicted by the Regional Brain Distribuition of Abeta and NFT Density: Two Profiles of Early Clinical Alzheimer Disease
Brain Weight at Ages 80+ is Predicted by the Regional Brain Distribuition of Abeta and NFT Density: Two Profiles of Early Clinical Alzheimer Disease
Fiona Caroline Crawford,
Roskamp Institute, USA
The Cystatin C Gene as A Novel Genetic Risk Factor for Late Onset Alzheimer's Disease
The Cystatin C Gene as A Novel Genetic Risk Factor for Late Onset Alzheimer's Disease
16:00—18:00
Poster Session 1: Presenilin and Other Genes Associated with AD Pathology
Innisbrook/Animas
17:00—18:00
Social Hour
Windom Peak
20:00—21:00
Coffee Available
Windom Peak
20:00—22:30
Estrogen, Genetics, and Alzheimer's Disease
Silverton
*
Richard Mayeux,
Columbia University, USA
Estrogen and Alzheimer's Disease
Estrogen and Alzheimer's Disease
Michael Hutton,
Eli Lilly Research Center, UK
The Molecular Genetics and Transgenic Modeling of Tauopathy
The Molecular Genetics and Transgenic Modeling of Tauopathy
Rudolph E. Tanzi,
Massachusetts General Hospital, USA
The Search for Novel AD Genes
The Search for Novel AD Genes
Sam Gandy,
Mount Sinai Medical Center, USA
Gonadal Hormones Control Brain Beta-Amyloid Levels in Animal Models and Circulating Beta-Amyloid Levels in Humans
Gonadal Hormones Control Brain Beta-Amyloid Levels in Animal Models and Circulating Beta-Amyloid Levels in Humans
07:00—08:00
Breakfast
Antlers
08:00—11:00
Amyloid beta-Peptide Cellular Interactions
Silverton
G. William Rebeck,
Massachusetts General Hospital, USA
Role of LDL-Receptor Related Protein (LRP) in AD Neuropathological Processes
Role of LDL-Receptor Related Protein (LRP) in AD Neuropathological Processes
David M. Stern,
Columbia University College of Physicians & Surgeons, USA
Receptor for Advanced Glycation Endproducts (RAGE): A Signal Transduction Receptor for beta-Sheet Fibrils that Activates Pathways Leading to Chronic Cellular Perturbation
Receptor for Advanced Glycation Endproducts (RAGE): A Signal Transduction Receptor for beta-Sheet Fibrils that Activates Pathways Leading to Chronic Cellular Perturbation
Paul A. Hyslop,
Eli Lilly and Company, USA
Secondary Structure of Amyloid-beta Peptide Determines the Ability of ApoE to Inhibit Abeta Proteolysis in vitro: A Model for Studying the Role of ApoE in Amyloid-beta Clearance.
Secondary Structure of Amyloid-beta Peptide Determines the Ability of ApoE to Inhibit Abeta Proteolysis in vitro: A Model for Studying the Role of ApoE in Amyloid-beta Clearance.
*
Carl W. Cotman,
University of California, Irvine, USA
Neuronal and Vascular Stress: The Pivotal Role of Beta-Amyloid in Disease Propagation
Neuronal and Vascular Stress: The Pivotal Role of Beta-Amyloid in Disease Propagation
09:20—09:40
Coffee Break
Windom Peak
11:00—13:00
Poster Setup
Innisbrook/Animas
14:00—16:00
Workshop 2: Animal Models
Silverton
*
Lennart Mucke,
Gladstone Institutes and University of California, San Francisco, USA
Overview and Discussion Leader
Overview and Discussion Leader
Giulio M. Pasinetti,
Mount Sinai School of Medicine, USA
COX-2 Dependent Cell Cycle Activities in Brain. Implications in the Clinical Progression of Alzheimer's Disease Dementia
COX-2 Dependent Cell Cycle Activities in Brain. Implications in the Clinical Progression of Alzheimer's Disease Dementia
Ottavio Arancio,
Columbia University Medical Center, USA
Age-Dependent Impairment of Hippocampal Long-Term Potentiation in Double Transgenic Mice Overexpression ABAD and mutAPP(V717F,K670M,N671L)
Age-Dependent Impairment of Hippocampal Long-Term Potentiation in Double Transgenic Mice Overexpression ABAD and mutAPP(V717F,K670M,N671L)
Thomas A. Bayer,
University of Saarland, Germany
Alpha-Synucleinin Alzheimer's Disease: Analysis of Postmortem Brains and APP/PS1 Transgenic Mice
Alpha-Synucleinin Alzheimer's Disease: Analysis of Postmortem Brains and APP/PS1 Transgenic Mice
Miguel A. Pappolla,
University of South Alabama, USA
16:00—18:00
Poster Session 2: Biology of Amyloid beta Peptide
Innisbrook/Animas
17:00—18:00
Social Hour
Windom Peak
20:00—21:00
Coffee Available
Windom Peak
20:00—21:30
Imaging for the Diagnosis and Monitoring of Treatment of AD
Silverton
Michael W. Weiner,
Veterans Affairs Medical Center, USA
MRI and MR Spectroscopic Imaging (MRSI) Studies of Alzheimer's Disease (AD) and Other Dementias
MRI and MR Spectroscopic Imaging (MRSI) Studies of Alzheimer's Disease (AD) and Other Dementias
*
Clifford R. Jack,
Mayo Clinic, USA
Prediction of AD with MRI-Based Hippocampal Volume and Mild Cognitive Impairment
Prediction of AD with MRI-Based Hippocampal Volume and Mild Cognitive Impairment
Daniel Skovronsky,
University of Pennsylvania School of Medicine, USA
Development of Radioligands for in vivo Imaging of Brain Amyloid
Development of Radioligands for in vivo Imaging of Brain Amyloid
07:00—08:00
Breakfast
Antlers
08:00—11:30
Interactions of Amyloid with the Vasculature and Microglia
Silverton
*
Alex E. Roher,
Sun Health Research Institute, USA
Interactions of Amyloid with the Vasculature and Microglia
Interactions of Amyloid with the Vasculature and Microglia
Shi Du Yan,
Columbia University, USA
Amyloid-beta Binding Alcohol Dehydrogenase (ABAD): An Intracellular Target of Amyloid beta (Abeta)
Amyloid-beta Binding Alcohol Dehydrogenase (ABAD): An Intracellular Target of Amyloid beta (Abeta)
Mark R. Emmerling,
Pfizer Global Research & Development, USA
Oligomeric Abeta and Neuronal Stress
Oligomeric Abeta and Neuronal Stress
Jorge Ghiso,
New York University School of Medicine, USA
Familial British Dementia: An Alternative Model of Neurodegeneration
Familial British Dementia: An Alternative Model of Neurodegeneration
Berislav Zlokovic,
University of Southern California, USA
Vascular Interaction of Abeta
Vascular Interaction of Abeta
09:20—09:40
Coffee Break
Windom Peak
17:00—18:00
Social Hour
Windom Peak
20:00—21:00
Coffee Available
Windom Peak
20:00—22:00
Clinical Development of Amyloid beta-Lowering Agents
Silverton
*
Perry B. Molinoff,
University of Pennsylvania, USA
Abeta-Modulation: The Next Generation of AD Therapeutics
Abeta-Modulation: The Next Generation of AD Therapeutics
Frederique Bard,
Janssen Alzheimer Immunotherapy, USA
Beta Amyloid Based Immunotherapeutic Approach to Alzheimer's Disease Treatment
Beta Amyloid Based Immunotherapeutic Approach to Alzheimer's Disease Treatment
Harry F. Dovey,
Elan Pharmaceuticals, Inc., USA
Functional gamma-Secretase Inhibitors Reduce Abeta Levels in PDAPP Mouse Brain
Functional gamma-Secretase Inhibitors Reduce Abeta Levels in PDAPP Mouse Brain
07:00—08:00
Breakfast
Antlers
08:00—11:00
Amyloid beta, apoE Biology and Lipoprotein Receptors
Silverton
*
David M. Stern,
Columbia University College of Physicians & Surgeons, USA
Paul Edward Fraser,
University of Toronto, Canada
Examining the Molecular Structure of Alzheimer's Amyloid-beta Protein
Examining the Molecular Structure of Alzheimer's Amyloid-beta Protein
Charles G. Glabe,
University of California, Irvine, USA
Mechanisms of Amyloid Accumulation and Pathogenesis in Alzheimer's Disease
Mechanisms of Amyloid Accumulation and Pathogenesis in Alzheimer's Disease
Robert W. Mahley,
J. David Gladstone Institutes, USA
Differential Effects of Cytosolic Apolipoprotein (Apo) E3 and ApoE4 on Neurite Outgrowth and the Cytoskeleton
Differential Effects of Cytosolic Apolipoprotein (Apo) E3 and ApoE4 on Neurite Outgrowth and the Cytoskeleton
Joachim Herz,
University of Texas Southwestern Medical Center, USA
Roles of Neuronal Apolipoprotein E Receptors in Brain Development and Neurodegeneration
Roles of Neuronal Apolipoprotein E Receptors in Brain Development and Neurodegeneration
09:20—09:40
Coffee Break
Windom Peak
11:00—13:00
Poster Setup
15:00—17:00
Workshop 4: Amyloid Angiopathy
Silverton
*
Robert Kisilevsky,
Queen's University, Canada
*
Berislav Zlokovic,
University of Southern California, USA
The Blood-Brain Barrier: Akey to Neurovascular Asynchron, Brain Senescence and Pathology Associated with Alzheimer's Disease
The Blood-Brain Barrier: Akey to Neurovascular Asynchron, Brain Senescence and Pathology Associated with Alzheimer's Disease
William E. Van Nostrand,
Stony Brook University, USA
Pathogenic Mechanisms of the Amyloid Beta Protein in Cerebral Amyloid Angiopathy
Pathogenic Mechanisms of the Amyloid Beta Protein in Cerebral Amyloid Angiopathy
Paula Grammas,
University of Oklahoma Health Sciences Center, USA
Brain Endothelial Cells are Key Participants in teh Pathogenesis of Neuronal Cell Death in Alzheimer's Disease
Brain Endothelial Cells are Key Participants in teh Pathogenesis of Neuronal Cell Death in Alzheimer's Disease
16:00—18:00
Poster Session 3: Amyloid Angiopathy
17:00—18:00
Social Hour
Windom Peak
20:00—21:00
Coffee Available
Windom Peak
20:00—22:30
Mechanisms of Neuronal Repair
Silverton
*
Melitta Schachner,
Nelson Biological Laboratories, USA
Cell Adhesion Molecules and Neuroprotection
Cell Adhesion Molecules and Neuroprotection
Ann Marie Schmidt,
New York University Langone Medical Center, USA
RAGE and Peripheral Nerve Repair
RAGE and Peripheral Nerve Repair
Valerie M.K. Verge,
University of Saskatchewan, Canada
Role of Neurotrophins in Adult Sensory Neuron Responses to Injury
Role of Neurotrophins in Adult Sensory Neuron Responses to Injury
07:00—08:00
Breakfast
Antlers
08:00—11:00
Approaches to Treatment of AD and Other Amyloidoses
Silverton
*
Berislav Zlokovic,
University of Southern California, USA
M. Kerry O'Banion,
University of Rochester School of Medicine & Densitstry, USA
Cyclooxygenases as Targets in Neuroinflammation and Neurodegeneration
Cyclooxygenases as Targets in Neuroinflammation and Neurodegeneration
Robert Kisilevsky,
Queen's University, Canada
Of Starch and Silk: In vivo Amyloid Formation and Strategies for Its Prevention
Of Starch and Silk: In vivo Amyloid Formation and Strategies for Its Prevention
Daniel H. Paris,
Oxford University, Thailand
Pro-Inflammatory Induction by Abeta in the Cerebrovasculature
Pro-Inflammatory Induction by Abeta in the Cerebrovasculature
Costantino Iadecola,
Weill Cornell Medicine, USA
Amyloid Beta: Roles in Cerebrovascular Regulation and Ischemic Damage
Amyloid Beta: Roles in Cerebrovascular Regulation and Ischemic Damage
09:20—09:40
Coffee Break
Windom Peak
15:00—16:00
Coffee Available
Windom Peak
15:00—17:00
Transgenic Models: Amyloid beta-Induced Stress in vivo
Silverton
*
Lennart Mucke,
Gladstone Institutes and University of California, San Francisco, USA
Abeta-Induced Neuronal Deficits and Their Modulation by ApoE Isoforms in vivo
Abeta-Induced Neuronal Deficits and Their Modulation by ApoE Isoforms in vivo
Karen Hsiao Ashe,
University of Minnesota, USA
Spatial Reference Memory in Transgenic Mice Overexpressing Mutant and Wild-Type APP
Spatial Reference Memory in Transgenic Mice Overexpressing Mutant and Wild-Type APP
Karen Duff,
Columbia University, USA
Cellular Responses to Amyloid and Tau
Cellular Responses to Amyloid and Tau
19:00—20:00
Social Hour
Windom Peak
20:00—22:00
Banquet
Silverton
09:00—12:00
Entertainment
Windom Peak
Departure
*Session Chair †Invited, not yet responded.
We gratefully acknowledge the generous grant for this conference provided by:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
